print logo

Contact Our Offices

Clinical Trials

Reset Text Size: A A A

Retinal Vein Occlusion

Active Studies

NEWTON (NCRVA and Regeneron)

A 1 year Prospective study of Aflibercept (Eylea) for previously treated Macular Edema associated with Central Retinal Vein Occlusion.

SCORE2 (NEI)

A 1 year study of comparative treatment between bevacizumab (Avastin) and aflibercept (Eylea) for Retinal Vein Occlusion.

Completed Studies

BRAVO (Genentech)

Phase 3 study of the efficacy and safety of ranibizumab (Lucentis) compared to sham injection in Branch Retinal Vein Occlusions.

COPERNICUS (Regeneron)

Phase 3 study of the safety, tolerability and biological effect of aflibercept (Eylea) for Central Retinal Vein Occlusions.

CRUISE (Genentech)

Phase 3 study of the efficacy and safety of ranibizumab (Lucentis) compared to sham injection in Central Retinal Vein Occlusions.

GENEVA (Allergan)

Phase 3 study of the efficacy of the Dexamethasone Intravitreal Implant (Ozurdex) in Retinal Vein Occlusions.

ICON (ICON Biosciences)

Phase 1 open label dose escalation study of the safety and tolerability of a sustained release Intravitreal Liquid Drug Delivery using Triamcinolone Acetonide.

SHORE (Genentech)

Phase 4 study evaluating different dosing regimens of ranibizumab (Lucentis).

VIBRANT (Regeneron)

A 1 year, Phase 3 study of the efficacy, safety and tolerability of aflibercept (Eylea) compared to Laser for the treatment of Branch Retinal Vein Occlusion.